With the industry’s largest network of PET biomarker production facilities worldwide, Siemens PETNET Solutions is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly’s molecular imaging agent in the United States, should it be FDA approved. Moreover, should Lilly’s molecular imaging agent be approved in markets outside the United States, the companies would consider expanding this commercial agreement to those markets as well.

“This commercial agreement with Lilly is another proof point that Siemens is at the forefront of providing leading diagnostic solutions that advance our mission: to provide physicians and patients with an integrated approach to diagnosing diseases,” said Britta Fuenfstueck, CEO of molecular imaging, Siemens Healthcare. “Optimized solutions, from tracer manufacturing to innovative scanner technologies of the Biograph product family of PET/CT [computed tomography] and PET/MR [magnetic resonance] products and related processing solutions, support an efficient diagnostic process.”

The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology (IT), and hearing aids.

Related Links:
Siemens Medical Solutions USA
Eli Lilly and Company